Citations

Showing 10 of 108162 citations.

The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression
Ramirez‐Peña, Esmeralda , Arnold, James M. , Shivakumar, Vinita, Joseph, Robiya , Vijay, Geraldine V. , Hollander, Petra den , Bhangre, Neeraja, Allegakoen, Paul, Prasad, Rishika , Conley, Zachary , Matés, José M. , Márquez, Javier , Vasaikar, Suhas , Soundararajan, Rama , Sreekumar, Arun , Mani, Sendurai A. , Vidhya Vijay, Geraldine, Prasad, Rishika , Chang, Jeffrey T.

Mayo Clinic

Cancers | October 23, 2019 | Volume: 11 | Issue: 10 | Pages: 1610

10.3390/cancers11101610 | PMID 31652551 Get It

Identifying bioenergetics that facilitate the epithelial to mesenchymal transition (EMT) in breast cancer cells may uncover targets to treat incurable metastatic disease. Metastasis is the number one cause of cancer-related deaths; therefore, it is urgent to identify new treatment strategies to prevent the initiation of metastasis. To characterize the bioenergetics of EMT, we compared metabolic activities and gene expression in cells induced to differentiate into the mesenchymal state with their epithelial counterparts. We found that levels of GLS2, which encodes a glutaminase, are inversely associated with EMT. GLS2 down-regulation was correlated with reduced mitochondrial activity and glutamine independence even in low-glucose conditions. Restoration of GLS2 expression in GLS2-negative breast cancer cells rescued mitochondrial activity, enhanced glutamine utilization, and inhibited stem-cell properties. Additionally, inhibition of expression of the transcription factor FOXC2, a critical regulator of EMT in GLS2-negative cells, restored GLS2 expression and glutamine utilization. Furthermore, in breast cancer patients, high GLS2 expression is associated with improved survival. These findings suggest that epithelial cancer cells rely on glutamine and that cells induced to undergo EMT become glutamine independent. Moreover, the inhibition of EMT leads to a GLS2-directed metabolic shift in mesenchymal cancer cells, which may make these cells susceptible to chemotherapies.
Design and reporting considerations for genetic screening tests
Hagenkord, Jill , Funke, Birgit , Hegde, Madhuri , Ferber, Matthew J. , Lebo, Matthew S. , Buchanan, Adam H. , Bick, David , Qian, Emily , Jacobs, Kevin B. , Lebo, Matthew

Mayo Clinic

No container title available | October 23, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27922v3 Get It

Testing asymptomatic individuals for unsuspected conditions is not new to the medical and public health communities and protocols to develop screening tests are well-established. However, the application of screening principles to inherited diseases presents unique challenges. Unlike most screening tests, the natural history and disease prevalence of most rare inherited diseases in an unselected population are unknown. It is difficult or impossible to obtain a “truth set” cohort for clinical validation studies. As a result, it is not possible to accurately calculate clinical positive and negative predictive values for “likely pathogenic” genetic variants, which are commonly returned in genetic screening assays. In addition, many of the genetic conditions included in screening panels do not have clinical confirmatory tests. All of these elements are typically required to justify the development of a screening test, according to the World Health Organization screening principles. Nevertheless, as the cost of DNA sequencing continues to fall, more individuals are opting to undergo genomic testing in the absence of a clinical indication. Despite the challenges, reasonable estimates can be deduced and used to inform test design strategies. Here, we review test design principles and apply them to genetic screening.
Differential estrogen‐receptor activation regulates extracellular matrix deposition in human airway smooth muscle remodeling via NF‐κB pathway
Ambhore, Nilesh Sudhakar , Kalidhindi, Rama Satyanarayana Raju, Hawse, John R. , Prakash, Y. S. , Sathish, Venkatachalem , Prakash, Y S , Sathish, Venkatachalem , Pabelick, Christina M.

Mayo Clinic

The FASEB Journal | October 23, 2019 | Volume: 33 | Issue: 12 | Pages: 13935-13950

10.1096/fj.201901340r | PMID 31638834 Get It

Altered airway smooth muscle (ASM) mass and extracellular matrix (ECM) deposition in airways are characteristic features of remodeling in asthma. Increased ECM production modulates ASM cell proliferation and leads to airway remodeling. Our previous studies showed that ASM from patients with asthma exhibited increased expression of estrogen receptor (ER)‐β, which upon activation down‐regulated ASM proliferation, implicating an important role for estrogen signaling in airway physiology. There is no current information on the effect of differential ER activation on ECM production. In this study, we evaluated the effect of ER‐α vs. ER‐β activation on ECM production, deposition, and underlying pathways. Primary human ASM cells isolated from asthmatics and nonasthmatics were treated with E 2 , an ER‐α agonist [propylpyrazoletriol (PPT)], and an ER‐β agonist [WAY‐200070 (WAY)] with TNF‐α or platelet‐derived growth factor (PDGF) followed by evaluation of ECM production and deposition. Expression of proteins and genes corresponding to ECM were measured using Western blotting and quantitative RT‐PCR with subsequent matrix metalloproteinase (MMP) activity. Molecular mechanisms of ER activation in regulating ECM were evaluated by luciferase reporter assays for activator protein 1 (AP‐1) and NF‐κB. TNF‐α or PDGF significantly ( P < 0.001) increased ECM deposition and MMP activity in human ASM cells, which was significantly reduced with WAY treatment but not with PPT. Furthermore, TNF‐α‐ or PDGF‐induced ECM gene expression in ASM cells was significantly reduced with WAY ( P < 0.001). Moreover, WAY significantly down‐regulated the activation of NF‐κB( P < 0.001) and AP‐1 ( P < 0.01, P < 0.05) in ASM cells from asthmatics and nonasthmatics. Overall, we demonstrate differential ER signaling in controlling ECM production and deposition. Activation of ER‐β diminishes ECM deposition via suppressing the NF‐κB pathway activity and might serve as a novel target to blunt airway remodeling.—Ambhore, N. S., Kalidhindi, R. S. R., Pabelick, C. M., Hawse, J. R., Prakash, Y. S., Sathish, V. Differential estrogen‐receptor activation regulates extracellular matrix deposition in human airway smooth muscle remodeling via NF‐κB pathway. FASEB J. 33, 13935‐13950 (2019). www.fasebj.org
Design and reporting considerations for genetic screening tests
Hagenkord, Jill , Funke, Birgit , Hegde, Madhuri , Ferber, Matthew J. , Lebo, Matthew S. , Buchanan, Adam H. , Bick, David , Qian, Emily , Jacobs, Kevin B. , Lebo, Matthew

Mayo Clinic

No container title available | October 23, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27922v2 Get It

Testing asymptomatic individuals for unsuspected conditions is not new to the medical and public health communities and protocols to develop screening tests are well-established. However, the application of screening principles to inherited diseases presents unique challenges. Unlike most screening tests, the natural history and disease prevalence of most rare inherited diseases in an unselected population are unknown. It is difficult or impossible to obtain a “truth set” cohort for clinical validation studies. As a result, it is not possible to accurately calculate clinical positive and negative predictive values for “likely pathogenic” genetic variants, which are commonly returned in genetic screening assays. In addition, many of the genetic conditions included in screening panels do not have clinical confirmatory tests. All of these elements are typically required to justify the development of a screening test, according to the World Health Organization screening principles. Nevertheless, as the cost of DNA sequencing continues to fall, more individuals are opting to undergo genomic testing in the absence of a clinical indication. Despite the challenges, reasonable estimates can be deduced and used to inform test design strategies. Here, we review test design principles and apply them to genetic screening.
Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non‐ulcer dyspepsia
Desai, Anshuman, Low, Phillip A. , Camilleri, Michael , Burton, Duane D. , Chakraborty, Subhankar , Bharucha, Adil E. , Chakraborty, Subhankar , Burton, Duane, Bharucha, A E , Singer, Wolfgang

Mayo Clinic

Neurogastroenterology & Motility | October 23, 2019 | Volume: 32 | Issue: 2 | Pages: No page available

10.1111/nmo.13744 | PMID 31642143 Get It

AbstractBackgroundThe relationship between cardiovascular and gastrointestinal (ie, plasma pancreatic polypeptide [PP] response to modified sham feeding [MSF]) indices of vagal function is unclear. Hyperglycemia inhibits PP secretion via vagally mediated mechanisms. Our aims were to (a) compare the PP response, (b) its relationship with glycemia, and (c) the relationship between PP response to MSF, gastric emptying (GE) of solids, and symptoms during GE study in healthy controls, patients with diabetic gastroenteropathy (DM), and non‐ulcer dyspepsia (NUD).MethodsIn 24 healthy controls, 40 DM, and 40 NUD patients, we measured plasma PP concentrations during MSF, cardiovagal functions, GE, and symptoms during a GE study.Key ResultsBaseline PP concentrations were higher in DM than in controls and NUD (P = .01), and in type 2 than in type 1 DM patients (P < .01). The PP increment during MSF was normal (≥20 pg/mL) in 70% of controls, 54% of DM, and 47% of NUD patients. Overall, the PP response and cardiovagal tests were concordant (P = .01). Among patients with a reduced PP increment with MSF, 7/10 of T1DM and 1/7 of T2DM patients had moderate or severe cardiovagal dysfunctions (P < .05). The PP response to MSF was not associated with GE.Conclusions & InferencesUp to 30% of healthy controls have a reduced PP increment during MSF, limiting the utility of this test to detect vagal injury. The PP response is more useful when it is normal than abnormal. A reduced PP response is more likely to be associated with cardiovagal dysfunctions in T1DM than in T2DM.
Expecting failure yet obtaining success
Mehra, Nandini, Asirvatham, Samuel J. , Asirvatham, Samuel J , Mehra, Nandini

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 23, 2019 | Volume: 30 | Issue: 12 | Pages: 2995-2997

10.1111/jce.14225 | PMID 31642149 Get It

Patterns of Sharps Handling and Disposal Among Insulin-Using Patients With Diabetes Mellitus
Montoya, Jordan, Thompson, Bithika , Boyle, Mary E., Leighton, Melinda E., Montoya, Jordan M, Thompson, Bithika M, Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | October 23, 2019 | Volume: 15 | Issue: 1 | Pages: 60-66

10.1177/1932296819882926 | PMID 31640410 Get It

Background: The objective of this study was to assess disposal patterns for “sharps” among a cohort of patients with diabetes mellitus (DM) receiving insulin therapy. Method: A convenience sample of inpatients and outpatients was surveyed about how they disposed of sharps, how often they reused lancets and needles, and what education they had received about proper disposal. Safe disposal was defined as discarding sharps into a formal sharps or sealable container; otherwise, disposal was categorized as unsafe. Results: Of 150 respondents, 56% were men and 75% were white. The mean (SD) age was 56 (15) years; duration of DM, 20 (13) years; and hemoglobin A 1c , 8.1% (2.0%). Half the respondents reused a lancet two or more times, and 21% reused an insulin needle two or more times. Thirty-eight percent of respondents discarded lancets unsafely, and 33% discarded insulin needles unsafely, typically by throwing these items into household trash. Most respondents (75%) discarded insulin pens, vials, cartridges, insulin pump supplies, and continuous glucose monitor sensors into household trash. Most (64%) indicated that they had not received education on safe sharps-disposal practices, and 84% had never visited their municipal website for information on medical waste disposal. Conclusion: Approximately one-third of patients unsafely disposed of sharps. Unsafe disposal could cause millions of sharps to appear in the municipal solid waste stream, thereby posing a substantial public health hazard. Point-of-care patient education is important, but a broader public health campaign may be required.
A Plant-Based Dietary Intervention for Preoperative Glucose Optimization in Diabetic Patients Undergoing Total Joint Arthroplasty
Drost, Jennifer M. , Probst, Nicholas E., Mi, Lanyu , Trentman, Terrence L. , Cook, Curtiss B. , Spangehl, Mark J.

Mayo Clinic

American Journal of Lifestyle Medicine | October 23, 2019 | Volume: 16 | Issue: 1 | Pages: 150-154

10.1177/1559827619879073 | PMID 35185437 Get It

Purpose. The purpose of this study was to assess the feasibility and effectiveness of a whole food plant-based diet (WFPBD) to improve day of surgery fasting blood glucose (FBG) among patients with type 2 diabetes (T2D). Patients and Methods. Ten patients with T2D scheduled for a total hip or total knee replacement were recruited. For 3 weeks preceding their surgeries, subjects were asked to consume an entirely WFPBD. Frozen WFPBD meals were professionally prepared and delivered to each participant for the 3 weeks prior to surgery. FBG was reassessed on the morning of surgery and compared with preintervention values. Compliance with the diet was assessed. Results. Mean age of subjects and reported duration of diabetes was 65 and 8 years, respectively, average hemoglobin A1c (HbA1c) was 6.6%, and 6 were women. Mean FBG decreased from 127 to 116 mg/dL ( P = .2). Five of the subjects experienced improvement in glycemic control, with an average decline of 11 mg/dL. Conclusion. A WFPBD is a potentially effective intervention to improve glycemic control among patients with T2D during the period leading up to surgery. Future controlled trials on a larger sample of patients to assess the impact of a WFPBD on glycemic control and surgical outcomes are warranted.
A Rare EGFR–SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib
Yang, Xiaobing , Ye, Yongsong , Bekaii‐Saab, Tanios , Zheng, Yaojie , Zhang, Hai-Bo , Bekaii-Saab, Tanios S , Li, Yong , Zhang, Haibo , Chen, Xian , Zhang, Yihong

Mayo Clinic

The Oncologist | October 22, 2019 | Volume: 25 | Issue: 3 | Pages: 203-207

10.1634/theoncologist.2019-0405 | PMID 32162810 Get It

Abstract Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Growing evidence supports gene fusions as good candidates for molecularly targeted therapy in CRC. Here we describe a case of a 63-year-old man who had a radical right hemicolectomy procedure 24 months ago. Pathological diagnosis indicated colorectal adenocarcinoma with stage pT4N2bMx. During re-examination in December 2016, positron emission tomography/computed tomography scans indicated relapse with multiple lymph nodes metastasis. Then the patient received a nine-cycle combination treatment of XELOX and bevacizumab and showed progressive disease (PD). Subsequently, the patient was treated with bevacizumab plus FOLFIRI for 2 months before discontinuation because of adverse events. Paraffin sections of postoperative colorectal tissue were subjected to next-generation sequencing, and epidermal growth factor receptor (EGFR) amplification and rare EGFR–SEPT14 fusion were identified. The patient then received erlotinib, an EGFR tyrosine kinase inhibitor (TKI), and achieved a partial response. However, the patient subsequently showed PD, and a new variant, EGFRvIII, appeared in metastasis, which may be involved in erlotinib resistance. We suggest that there is value in treating patients harboring EGFR fusions with EGFR TKI therapy, and EGFR–SEPT14 fusion may be used as a therapeutic target for CRC. Key Points To the authors' knowledge, this is the first report of EGFR–SEPT14 fusion in colorectal cancer. The patient achieved a partial response after treatment with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib. This report expands the list of gene fusions in colorectal cancer and highlights new targets for the therapeutic intervention. EGFRvIII may be involved in erlotinib resistance, which is rare in colorectal cancer.
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma
Chen, Robert W., Fenske, Timothy S. , Shea, Thomas C., Barr, Paul M. , Leonard, John P. , Friedberg, Jonathan W. , Smith, Sonali M. , Barr, Paul M , Kamdar, Manali , Li, Hongli , Rimsza, Lisa M. , LeBlanc, Michael , Phillips, Tycel , Kahl, Brad S.

Mayo Clinic

Blood Advances | October 22, 2019 | Volume: 3 | Issue: 20 | Pages: 3132-3135

10.1182/bloodadvances.2019000526 | PMID 31648328 Get It

Key Points Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.